Liquid chromatographic determination of irinotecan and three major metabolites in human plasma, urine and feces

被引:77
作者
Sparreboom, A
de Bruijn, P
de Jonge, MJA
Loos, WJ
Stoter, G
Verweij, J
Nooter, K
机构
[1] Rotterdam Canc Inst, Lab Expt Chemotherapy & Pharmacol, Dept Med Oncol, Daniel den Hoed Klin, NL-3008 AE Rotterdam, Netherlands
[2] Univ Rotterdam Hosp, NL-3008 AE Rotterdam, Netherlands
来源
JOURNAL OF CHROMATOGRAPHY B | 1998年 / 712卷 / 1-2期
关键词
irinotecan;
D O I
10.1016/S0378-4347(98)00147-9
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A new simple reversed-phase high-performance Liquid chromatographic method was developed for the determination of irinotecan (CPT-II) and three metabolites in human plasma, urine and feces homogenate. The metabolites of interest were 7-ethyl-10-hydroxycamptothecin (SN-38), its beta-glucuronide derivative (SN-38G) and 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino]carbonyloxycamptothecin (RPR 121056A; also referred to as APC). Sample pretreatment from the various biological matrices involved a rapid protein precipitation with simultaneous solvent extraction of 250-mu l aliquots of sample with 500 mu l of methanol-5% (w/v) aqueous perchloric acid (1:1, v/v). Separation of the compounds was achieved on an analytical column packed with Hypersil ODS material (100X4.6 mm I.D., 5 mu m), and isocratic elution with a mixture of methanol-0.1 M ammonium acetate containing 10 mM tetrabutylammonium sulphate (30:70, v/v), pH 5.3 (hydrochloric acid). The column effluent was monitored at excitation and emission wavelengths of 355 and 515 nm, respectively. Results from a 4-day validation study indicated that this single-run determination allows for simple, simultaneous and rapid quantitation and identification of all analytes with excellent reliability. The described procedure permits the analysis of patient samples, and will be implemented in future studies to investigate the complete metabolic fate and disposition of CPT-II in cancer patients. (C) 1998 Elsevier Science B.V, All rights reserved.
引用
收藏
页码:225 / 235
页数:11
相关论文
共 28 条
  • [1] ATSUMI R, 1995, BIOL PHARM BULL, V18, P1024
  • [2] IDENTIFICATION OF THE METABOLITES OF IRINOTECAN, A NEW DERIVATIVE OF CAMPTOTHECIN, IN RAT BILE AND ITS BILIARY-EXCRETION
    ATSUMI, R
    SUZUKI, W
    HAKUSUI, H
    [J]. XENOBIOTICA, 1991, 21 (09) : 1159 - 1169
  • [3] Semisynthesis of RPR 121056A, a major metabolite of irinotecan (CPT-11)
    Bourzat, JD
    Vuilhorgne, M
    Rivory, LP
    Robert, J
    Commercon, A
    [J]. TETRAHEDRON LETTERS, 1996, 37 (35) : 6327 - 6330
  • [4] TOPOISOMERASE-I INHIBITORS - TOPOTECAN AND IRENOTECAN
    CREEMERS, GJ
    LUND, B
    VERWEIJ, J
    [J]. CANCER TREATMENT REVIEWS, 1994, 20 (01) : 73 - 96
  • [5] Determination of irinotecan (CPT-11) and its active metabolite SN-38 in human plasma by reversed-phase high-performance liquid chromatography with fluorescence detection
    deBruijn, P
    Verweij, J
    Loos, WJ
    Nooter, K
    Stoter, G
    Sparreboom, A
    [J]. JOURNAL OF CHROMATOGRAPHY B, 1997, 698 (1-2): : 277 - 285
  • [6] DEJONGE MJA, 1997, EUR J CANCER S8, V33, pS251
  • [7] Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development
    Gerrits, CJH
    deJonge, MJA
    Schellens, JHM
    Stoter, G
    Verweij, J
    [J]. BRITISH JOURNAL OF CANCER, 1997, 76 (07) : 952 - 962
  • [8] GUPTA E, 1994, CANCER RES, V54, P3723
  • [9] Haaz MC, 1998, CANCER RES, V58, P468
  • [10] Glucuronidation of SN-38, the active metabolite of irinotecan, by human hepatic microsomes
    Haaz, MC
    Rivory, L
    Jantet, S
    Ratanasavanh, D
    Robert, J
    [J]. PHARMACOLOGY & TOXICOLOGY, 1997, 80 (02): : 91 - 96